Compounds useful for increasing neurogenesis in neural tissue

Abstract

The invention, described herein, is directed to the use of acetyl. L-carnitine, or propionyl L-carnitine, or a salt thereof, for preparing a medicament for increasing neurogenesis in neural tissue; in winch said increased neurogenesis is useful for preventing central nervous system disorders due to ageing or genetic predisposition.

1 . (canceled) 
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . (canceled) 
     
     
         7 . (canceled) 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . Method for preventing central nervous system disorders, by administering to a patient in need thereof an amount of acetyl L-carnitine, or propionyl L-carnitine or a salt thereof, suitable for increasing neurogenesis. 
     
     
         11 . Method of  claim 10 , in which the central nervous system disorders are due to aging or genetic predisposition. 
     
     
         12 . Method for increasing neurogenesis, by administering to a patient in need thereof a suitable amount of acetyl L-carnitine, or propionyl L-carnitine, or a salt thereof, for preventing central nervous system disorders. 
     
     
         13 . Method of  claim 12 , in which the central nervous system disorders are due to aging or genetic predisposition. 
     
     
         14 . Method for increasing neurogenesis, in which said increased neurogenesis is useful for preventing central nervous system disorders, by chronically administering to a patient in need thereof a suitable amount of acetyl L-carnitine, or propionyl L-carnitine, or a salt thereof. 
     
     
         15 . Method of  claim 14 , in which the central nervous system disorders are due to ageing or genetic predisposition. 
     
     
         16 . Method of  claim 12 , wherein the salt of acetyl L-carnitine, or propionyl L-carnitine, is selected from the group consisting of: chloride, bromide, orotate, aspartate, acid aspartate, acid citrate, magnesium citrate, phosphate, acid phosphate, fumarate and acid fumarate, magnesium fumarate, lactate, maleate and acid maleate, oxalate, acid oxalate, pamoate, acid pamoate, sulphate, acid sulphate, glucose phosphate, tartrate and acid tartrate, glycerophosphate, mucate, magnesium tartrate, 2-amino-ethanesulphonate, magnesium 2amino-ethanesulphonate, methanesulphonate, choline tartrate, trichloroacetate, and trifluoroacetate. 
     
     
         17 . Method of  claim 12 , wherein the acetyl L-carnitine, or propionyl L-carnitine, are administered in a dose of 0.1 to 4.00 g/day in a single or multiple doses. 
     
     
         18 . Method of  claim 17 , wherein the acetyl L-carnitine, or propionyl L-carnitine, are administered in a dose of 1 to 2.00 g/day, in a single or multiple doses. 
     
     
         19 . Method of  claim 18 , wherein the acetyl L-carnitine, or propionyl L-carnitine, are administered in a dose of 1.5 g/day, in a single or multiple doses. 
     
     
         20 . Method of  claim 12 , wherein the acetyl L-carnitine, or propionyl L-carnitine, are administered by an enteral or parenteral route selected from: oral, subcutaneous, transdermal, intraperitoneal, intramuscular, in vein, intracerebroventricular, intraparenchymal, intrathecal, intracranial, buccal, mucosal, nasal, pulmonary, rectal or liposomal administration. 
     
     
         21 . Method according to  claim 12 , wherein the central nervous system disorder is selected from group consisting of: neurodegenerative disorders, Parkinson's disease and Parkinsonian disorders, Huntington's disease, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, Shy-Drager syndrome, Lewy body disease, spinal ischemia, ischemic stroke, cerebral infarction, geriatric dementia, other cognitive impairments and depression.